These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 17520365)

  • 1. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS.
    Yang J; Lee HR; Low K; Chatterjee S; Pimentel M
    Dig Dis Sci; 2008 Jan; 53(1):169-74. PubMed ID: 17520365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin.
    Cuoco L; Salvagnini M
    Minerva Gastroenterol Dietol; 2006 Mar; 52(1):89-95. PubMed ID: 16554709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test.
    Low K; Hwang L; Hua J; Zhu A; Morales W; Pimentel M
    J Clin Gastroenterol; 2010 Sep; 44(8):547-50. PubMed ID: 19996983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small intestinal bacterial overgrowth produces symptoms in irritable bowel syndrome which are improved by rifaximin. A pilot study.
    Moraru IG; Portincasa P; Moraru AG; Diculescu M; Dumitraşcu DL
    Rom J Intern Med; 2013; 51(3-4):143-7. PubMed ID: 24620626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small intestinal bacterial overgrowth is associated to symptoms in irritable bowel syndrome. Evidence from a multicentre study in Romania.
    Moraru IG; Moraru AG; Andrei M; Iordache T; Drug V; Diculescu M; Portincasa P; Dumitrascu DL
    Rom J Intern Med; 2014; 52(3):143-50. PubMed ID: 25509557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small intestinal bacterial overgrowth as a cause for irritable bowel syndrome: guilty or not guilty?
    Aziz I; Törnblom H; Simrén M
    Curr Opin Gastroenterol; 2017 May; 33(3):196-202. PubMed ID: 28257307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic prostatitis and small intestinal bacterial overgrowth: effect of rifaximin.
    Weinstock LB; Geng B; Brandes SB
    Can J Urol; 2011 Aug; 18(4):5826-30. PubMed ID: 21854715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibiotic treatment of constipation-predominant irritable bowel syndrome.
    Pimentel M; Chang C; Chua KS; Mirocha J; DiBaise J; Rao S; Amichai M
    Dig Dis Sci; 2014 Jun; 59(6):1278-85. PubMed ID: 24788320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome.
    Zhuang X; Tian Z; Luo M; Xiong L
    BMC Gastroenterol; 2020 Jun; 20(1):187. PubMed ID: 32532214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Rifaximin application in the overgrowth bacterial syndrome in the small intestine in patients after cholecystectomy].
    Mechetina TA; Il'chenko AA; Lychkova AE
    Eksp Klin Gastroenterol; 2011; (3):93-100. PubMed ID: 21695956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects.
    Pimentel M; Morales W; Chua K; Barlow G; Weitsman S; Kim G; Amichai MM; Pokkunuri V; Rook E; Mathur R; Marsh Z
    Dig Dis Sci; 2011 Jul; 56(7):2067-72. PubMed ID: 21559740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rifaximin: new therapeutic indication and future directions.
    Rivkin A; Gim S
    Clin Ther; 2011 Jul; 33(7):812-27. PubMed ID: 21741091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial.
    Pimentel M; Park S; Mirocha J; Kane SV; Kong Y
    Ann Intern Med; 2006 Oct; 145(8):557-63. PubMed ID: 17043337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
    Rivkin A; Rybalov S
    Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome.
    Scarpellini E; Giorgio V; Gabrielli M; Filoni S; Vitale G; Tortora A; Ojetti V; Gigante G; Fundarò C; Gasbarrini A
    Eur Rev Med Pharmacol Sci; 2013 May; 17(10):1314-20. PubMed ID: 23740443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rifaximin: The Revolutionary Antibiotic Approach for Irritable Bowel Syndrome.
    Triantafyllou K; Sioulas AD; Giamarellos-Bourboulis EJ
    Mini Rev Med Chem; 2015; 16(3):186-92. PubMed ID: 26202193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of rifaximin on intestinal bacterial overgrowth in Crohn's disease as assessed by the H2-Glucose Breath Test.
    Biancone L; Vernia P; Agostini D; Ferrieri A; Pallone F
    Curr Med Res Opin; 2000; 16(1):14-20. PubMed ID: 16422030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months.
    Meyrat P; Safroneeva E; Schoepfer AM
    Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1084-93. PubMed ID: 23066911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of rifaximin treatment period according to lactulose breath test values in nonconstipated irritable bowel syndrome subjects.
    Bae S; Lee KJ; Kim YS; Kim KN
    J Korean Med Sci; 2015 Jun; 30(6):757-62. PubMed ID: 26028929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence.
    Sharara AI; Aoun E; Abdul-Baki H; Mounzer R; Sidani S; Elhajj I
    Am J Gastroenterol; 2006 Feb; 101(2):326-33. PubMed ID: 16454838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.